Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label Phase 2 Study to Assess the Effect of C5aR Antagonist Therapy by CCX168 Oral Administration on ex Vivo Thrombus Formation and Disease Activity in ESRD Patients With Atypical Hemolytic Uremic Syndrome

Next Previous
X
Search
Trial Profile

An Open-label Phase 2 Study to Assess the Effect of C5aR Antagonist Therapy by CCX168 Oral Administration on ex Vivo Thrombus Formation and Disease Activity in ESRD Patients With Atypical Hemolytic Uremic Syndrome

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 17 Sep 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Avacopan (Primary)
  • Indications Atypical Haemolytic Uraemic Syndrome
  • Focus Proof of concept; Therapeutic Use
  • Acronyms ACCESS
  • Sponsors ChemoCentryx

    • Most Recent Events

    • 02 Mar 2017 Status changed from recruiting to discontinued.
    • 07 Nov 2016 According to ChemoCentryx media release, the company has announced positive data (n=5) from this pilot phase II trial.
    • 08 Aug 2016 According to a ChemoCentryx media release, the company expects to report early results from this trial in late 2016.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top